• Skip to primary navigation
  • Skip to main content
AMRA MedicalAMRA Medical

AMRA Medical

Precision for Decision

  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Set Up
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Media
  • About Us
    • About AMRA
    • Our Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us

AMRA Medical’s Research Links Muscle Composition to Risk of Death

October 29, 2021
  • Facebook
  • Twitter
  • LinkedIn
  • Mail

[Click on the image above to watch the video]

Linköping, Sweden, October 29, 2021: In collaboration with Linköping University and Virginia Commonwealth University, AMRA researchers found that adverse muscle composition—defined by low muscle volume coupled with high muscle fat infiltration—was a strong and independent predictor of all-cause mortality. This research can potentially help guide the design of future clinical trials and drug development programs. The project is part of the EU’s H2020 Research and Innovation Programme, funded by CoMorMent (grant agreement/project number 847776) and is accepted for publication in the Journal of Cachexia, Sarcopenia and Muscle (JCSM).

Older adults progressively lose muscle mass and strength as they age – a process that is intensified in individuals with metabolic disorders, like type 2 diabetes and non-alcoholic steatohepatitis (NASH). The associations between muscle mass, function, and quality, and mortality are unclear, making it difficult to identify the most vulnerable individuals.

By using UK Biobank data and AMRA’s magnetic resonance imaging (MRI) measurements, the researchers found that adverse muscle composition was a strong and independent predictor of all-cause mortality. In fact, adverse muscle composition had a hazard ratio magnitude comparable to that of a previous cancer diagnosis or smoking. Over 40,000 participants were scanned using a 6-minute MRI protocol and images were analyzed for thigh fat-free muscle volume (FFMV) and muscle fat infiltration (MFI). At imaging, adverse muscle composition was detected in 10.5% of participants, and the risk of death from any cause in adverse muscle composition was 3.7 times more likely compared to normal muscle composition.

What’s more, adverse muscle composition was highly associated with all-cause mortality regardless of functional performance (based on hand-grip strength, walking pace, and falls). The combination of poor function with adverse muscle composition was most closely associated with death.

AMRA’s previous findings have revealed that adverse muscle composition was prevalent in 14% of individuals with non-alcoholic fatty liver disease (NAFLD). This phenotype—NAFLD with adverse muscle composition—was associated with a very high prevalence of metabolic comorbidities. Connecting this research with the present study demonstrates that adverse muscle composition is a prevalent, yet highly vulnerable phenotype. 1 Together, this research indicates that objectively measuring muscle health is an important consideration in clinical trial design and could predict liver disease progression and poor patient outcomes.

Read the full publication titled “Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study“ at https://onlinelibrary.wiley.com/doi/full/10.1002/jcsm.12834.

About AMRA Medical

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI.

About UKBB

UK Biobank is a large-scale biomedical database and research resource, containing in-depth genetic and health information from half a million UK participants. The database, which is regularly augmented with additional data, is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UK Biobank’s research resource is a major contributor to the advancement of modern medicine and treatment and has enabled several scientific discoveries that improve human health.

Contact
Rosemary Shull
SVP Global BD & Marketing
rosemary.shull@amramedical.com

1Linge J, et al. JHEP 2020. https://doi.org/10.1016/j.jhepr.2020.100197

All posts
  • Facebook
  • Twitter
  • LinkedIn
  • Mail
AMRA Medical
Follow us

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

  • Data Privacy Policy
  • Cookie Policy

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support

Newsletter

© 2025 AMRA Medical AB
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}